Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Contribution of classical end-joining to PTEN inactivation in p53-mediated glioblastoma formation and drug-resistant survival.

Kang YJ, Balter B, Csizmadia E, Haas B, Sharma H, Bronson R, Yan CT.

Nat Commun. 2017 Jan 17;8:14013. doi: 10.1038/ncomms14013.

2.

PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.

Roodakker KR, Elsir T, Edqvist PD, Hägerstrand D, Carlson J, Lysiak M, Henriksson R, Pontén F, Rosell J, Söderkvist P, Stupp R, Tchougounova E, Nistér M, Malmström A, Smits A.

Oncotarget. 2016 Nov 8;7(45):72431-72442. doi: 10.18632/oncotarget.11957.

3.

TGFβ-Responsive HMOX1 Expression Is Associated with Stemness and Invasion in Glioblastoma Multiforme.

Ghosh D, Ulasov IV, Chen L, Harkins LE, Wallenborg K, Hothi P, Rostad S, Hood L, Cobbs CS.

Stem Cells. 2016 Sep;34(9):2276-89. doi: 10.1002/stem.2411. Epub 2016 Jul 4.

PMID:
27354342
4.
5.

MDM2 inhibition rescues neurogenic and cognitive deficits in a mouse model of fragile X syndrome.

Li Y, Stockton ME, Bhuiyan I, Eisinger BE, Gao Y, Miller JL, Bhattacharyya A, Zhao X.

Sci Transl Med. 2016 Apr 27;8(336):336ra61. doi: 10.1126/scitranslmed.aad9370.

6.

Inactivation of the ATMIN/ATM pathway protects against glioblastoma formation.

Blake SM, Stricker SH, Halavach H, Poetsch AR, Cresswell G, Kelly G, Kanu N, Marino S, Luscombe NM, Pollard SM, Behrens A.

Elife. 2016 Mar 17;5. pii: e08711. doi: 10.7554/eLife.08711.

7.

ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.

Koschmann C, Calinescu AA, Nunez FJ, Mackay A, Fazal-Salom J, Thomas D, Mendez F, Kamran N, Dzaman M, Mulpuri L, Krasinkiewicz J, Doherty R, Lemons R, Brosnan-Cashman JA, Li Y, Roh S, Zhao L, Appelman H, Ferguson D, Gorbunova V, Meeker A, Jones C, Lowenstein PR, Castro MG.

Sci Transl Med. 2016 Mar 2;8(328):328ra28. doi: 10.1126/scitranslmed.aac8228.

8.

Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance.

Fidoamore A, Cristiano L, Antonosante A, d'Angelo M, Di Giacomo E, Astarita C, Giordano A, Ippoliti R, Benedetti E, Cimini A.

Stem Cells Int. 2016;2016:6809105. doi: 10.1155/2016/6809105. Epub 2016 Jan 6. Review.

9.

Impaired TGF-β induced growth inhibition contributes to the increased proliferation rate of neural stem cells harboring mutant p53.

Kumar P, Naumann U, Aigner L, Wischhusen J, Beier CP, Beier D.

Am J Cancer Res. 2015 Oct 15;5(11):3436-45. eCollection 2015.

10.

P53 functional abnormality in mesenchymal stem cells promotes osteosarcoma development.

Velletri T, Xie N, Wang Y, Huang Y, Yang Q, Chen X, Chen Q, Shou P, Gan Y, Cao G, Melino G, Shi Y.

Cell Death Dis. 2016 Jan 21;7:e2015. doi: 10.1038/cddis.2015.367. Review.

11.

Phosphorylation Regulates Id2 Degradation and Mediates the Proliferation of Neural Precursor Cells.

Sullivan JM, Havrda MC, Kettenbach AN, Paolella BR, Zhang Z, Gerber SA, Israel MA.

Stem Cells. 2016 May;34(5):1321-31. doi: 10.1002/stem.2291. Epub 2016 Feb 1.

12.

PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype.

Duan S, Yuan G, Liu X, Ren R, Li J, Zhang W, Wu J, Xu X, Fu L, Li Y, Yang J, Zhang W, Bai R, Yi F, Suzuki K, Gao H, Esteban CR, Zhang C, Izpisua Belmonte JC, Chen Z, Wang X, Jiang T, Qu J, Tang F, Liu GH.

Nat Commun. 2015 Dec 3;6:10068. doi: 10.1038/ncomms10068.

13.

How neuronal activity regulates glioma cell proliferation.

Filbin MG, Segal RA.

Neuro Oncol. 2015 Dec;17(12):1543-4. doi: 10.1093/neuonc/nov188. Epub 2015 Sep 10. No abstract available.

14.

Rapid tumor induction in zebrafish by TALEN-mediated somatic inactivation of the retinoblastoma1 tumor suppressor rb1.

Solin SL, Shive HR, Woolard KD, Essner JJ, McGrail M.

Sci Rep. 2015 Sep 8;5:13745. doi: 10.1038/srep13745.

15.
16.

Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion.

Venkatesh HS, Johung TB, Caretti V, Noll A, Tang Y, Nagaraja S, Gibson EM, Mount CW, Polepalli J, Mitra SS, Woo PJ, Malenka RC, Vogel H, Bredel M, Mallick P, Monje M.

Cell. 2015 May 7;161(4):803-16. doi: 10.1016/j.cell.2015.04.012. Epub 2015 Apr 23.

17.

Inhibition of oxidative metabolism leads to p53 genetic inactivation and transformation in neural stem cells.

Bartesaghi S, Graziano V, Galavotti S, Henriquez NV, Betts J, Saxena J, Minieri V, A D, Karlsson A, Martins LM, Capasso M, Nicotera P, Brandner S, De Laurenzi V, Salomoni P.

Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1059-64. doi: 10.1073/pnas.1413165112. Epub 2015 Jan 12. Erratum in: Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1401. Minieri, Valentina [added].

18.

Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.

Kim E, Wang Y, Kim SJ, Bornhorst M, Jecrois ES, Anthony TE, Wang C, Li YE, Guan JL, Murphy GG, Zhu Y.

Elife. 2014 Dec 23;3. doi: 10.7554/eLife.05151.

19.

A computational model incorporating neural stem cell dynamics reproduces glioma incidence across the lifespan in the human population.

Bauer R, Kaiser M, Stoll E.

PLoS One. 2014 Nov 19;9(11):e111219. doi: 10.1371/journal.pone.0111219. eCollection 2014.

20.

Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone.

Piccirillo SG, Spiteri I, Sottoriva A, Touloumis A, Ber S, Price SJ, Heywood R, Francis NJ, Howarth KD, Collins VP, Venkitaraman AR, Curtis C, Marioni JC, Tavaré S, Watts C.

Cancer Res. 2015 Jan 1;75(1):194-202. doi: 10.1158/0008-5472.CAN-13-3131. Epub 2014 Nov 18.

Supplemental Content

Support Center